What are the common side effects of neratinib (neratinib) and how to effectively deal with them

Neratinib, also known as neratinib, is an oral, irreversible pan-HER tyrosine kinase inhibitor, mainly used for adjuvant treatment of HER2-positive breast cancer, especially for continued consolidation therapy after early completion of trastuzumab treatment. As a targeted therapy, neratinib has shown significant effects in delaying recurrence and improving disease-free survival in clinical practice. However, like most targeted drugs, it can come with a range of side effects. Correctly understanding these adverse reactions and taking effective countermeasures are crucial to improving patients' treatment compliance and quality of life.

1. The most common side effect: diarrhea

The most common adverse reaction in neratinib treatment is diarrhea. Almost more than 90% of patients will experience varying degrees of diarrhea in the early stages of treatment, of which about 30%patients have severe diarrhea of Grade 3 or above (ie, the number of bowel movements per day is ≥7 times, or accompanied by dehydration, electrolyte imbalance, etc.). This side effect is usually most noticeable within the first two weeks of taking the drug and is the main reason why patients interrupt or reduce their dose.

Countermeasures:

Preventive medication: According to the guideline recommendation, patients should take anti-diarrheal drugs, such as loperamide (Loperamide) before starting to use neratinib. The recommended plan is to start taking loperamide on the first day and take it at a fixed dose every day for more than 2 weeks, and then gradually reduce the dose according to the condition of diarrhea.

Diet adjustment: avoid greasy, spicy, raw and cold foods, and maintain a light and easy-to-digest diet. Drink plenty of water to prevent dehydration.

Close monitoring and medical treatment: If persistent diarrhea occurs or is accompanied by fever, vomiting, or obvious dehydration, you should seek medical treatment immediately. Infusion, electrolyte supplementation, or even a short withdrawal of medication may be required.

2. Abnormal liver function

Neratinib may also cause **elevated liver enzymes (ALT, AST)** and other liver function abnormalities, especially during long-term use. Most of these side effects are mild to moderate, and a small number of patients may develop hepatotoxicity grade 3 or above.

Countermeasures:

Regular examination: It is recommended to test liver function every 1-2 weeks before and during treatment, especially at the beginning of treatment or when used in combination with other hepatotoxic drugs.

Reduce or suspend the dose: If liver enzymes are found to be significantly elevated or symptoms such as jaundice, fatigue, right upper quadrant discomfort, etc., the dose should be adjusted in a timely manner or the drug should be temporarily discontinued, and use should be resumed cautiously after liver function is restored.

Avoid concomitant use of drugs: During the use of neratinib, you should avoid using other drugs that can damage the liver, such as certain antibiotics, antipyretics and analgesics, etc.

3. Nausea and vomiting

Some patients report gastrointestinal discomfort such as nausea, vomiting or loss of appetite during medication. Although these symptoms are less common than diarrhea, they can also affect patients' quality of life and willingness to take medication.

Countermeasures:

Use antiemetics as needed: If there is obvious nausea, antiemetics such as ondansetron and metoclopramide can be used for symptomatic treatment.

Adjustment of medication time: You can try taking neratinib after meals to avoid irritating the gastric mucosa on an empty stomach.

Dietary intervention: It is recommended to eat small amounts frequently, avoid fasting, and choose protein-rich and easy-to-digest foods, such as bananas, rice porridge, toast, etc.

4. Rash and dry skin

Because neratinib targets the HER family of receptors, of which EGFR is also present in skin cells, some patients may experience skin reactions such as rash, itching, or dryness and scaling during treatment.

Countermeasures:

Gentle skin care: Use mild facial cleanser and moisturizer, and avoid using irritating skin care products.

Sun protection measures: Pay attention to sun protection when going out to avoid ultraviolet rays that aggravate the rash.

Drug intervention: If the rash is severe, antihistamines or topical hormone ointments can be used under the guidance of a doctor to relieve symptoms.

5. Other possible adverse reactions

In addition to the above common discomforts, neratinib may also cause other side effects, such as:

Increased fatigue: Some patients report that they are prone to feeling fatigue or reduced physical fitness during medication, and should pay attention to rest and nutritional supplements.

Stomatitis or dry mouth: It is recommended to keep the mouth clean and use mouthwash to relieve discomfort.

Urinary frequency or urgency: Individual patients may experience urinary system-related reactions, which are usually mild and do not affect treatment.

6. Suggestions for dosage adjustment

In clinical use, if the patient experiences serious side effects, the doctor can adjust the dose according to the degree of symptoms. The recommended initial dose of neratinib is 240mg/(one-time oral administration), but if the patient has poor tolerance, it can be reduced to 200mg or 160mg/day, or even discontinued for a short period of time. Studies have shown that appropriate adjustment of dosage does not significantly affect its anti-tumor efficacy, but can instead improve patient compliance and long-term benefits.

7. Psychological support and health management

Targeted therapy is a long-term process, and patients are often accompanied by anxiety, fear of side effects, changes in life rhythm, etc. during medication. In addition to drug response, doctors and family members should also provide positive psychological support, encourage patients to record daily medication and discomfort reactions, and form a good communication and feedback mechanism to deal with treatment challenges more scientifically.

Neratinib, as an important targeted drug for adjuvant treatment ofHER2 positive breast cancer, may indeed cause a series of side effects, especially diarrhea. However, as long as patients are fully prepared before treatment, actively prevent and monitor during medication, seek medical advice promptly and adjust dosage when discomfort occurs, most side effects can be controlled and alleviated. Through standardized management and collaborative collaboration between doctors and patients, neratinib is expected to safely and efficiently bring better survival benefits to more breast cancer patients.

Reference materials:https://www.drugs.com/